Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Aug 29, 2024 2:45pm
396 Views
Post# 36201679

Moving along…slow but sure

Moving along…slow but sure

First, I'm away on a bit of a healing break.
internet is poor at best here.
Lots going on in the geopolitical & financial world.
Too much to mention.
Never in my 40+ years of being an investor have I ever appreciated having 98% of our $$ professionally managed.
Doing the math, ONC represents at most 1% of our investable assets.
i do hold a few other stocks. Total other end of spectrum.
Thst being solid, dividend paying profitable companies.
Why the preface?
As I have said many times over. I could care less about the day- day stock price off ONC.
i do care a lot about their potential.
why?
Looking at the fundamentals/ background.
onc has reached a crossroads.
perhaps, we have been here before? Is this time different?
Recent analysts have given 12 month price targets average $5ps ( usd).
None of the calculations include a complete buyout.
Why so long.., why not yet?
Actully there was a potential deal, Some time around 2017.
The word was, regardless of price, the aquiiring company would hav3 total control of Pelareoreps future.
Including shutting it down.
since then, the whole trial & evaluation of results have lead to intersting & very valuable conclusions.
1. Pela is best utilized as a co- therapy.
2. priming the imune system , can expand the patient base, of existing standard of care cancer treatments.
2. The pancreatic cancer treatment exceeded all expectations & granted FDA fast track approval. & The support of originally PanCan " precicion promise" , now  CGAR 
3. The pancreatic cancer phase 3 trial is expected to begin early 2025.
4. The long awaited MBc overall survival results are due before the end if this year.
5. While the panc cancer phase 3, seems to have direction, the MBc does not. Company's web site says regarding MBc ( TBD).....The recent public presentations discussed that. Simple language.
They need solid results to take to the table as part of negotiations to get the best deal possible.
stepping back from the details.
Should Pelareorep get approved for either pancreatic or MBc cancers. The upside is well beyond anyone's imagination.
Getting approval for both!, would move Onc into blockbuster status.
lots said.
My bottom line has not changed.
if they fail, my losses are minimal.
if they sucseed my potential gains are huge.
The $billion buy out opportunity is still very possible.
Next set if MBc O.S. Resukts and/ or the progress of pancreatic phase 3, will be a good start in that direction.
until then, lots of waiting.
Repeating the irony. The longer MBc O.S. Reults take the better.
the events they are talking about , are patents dieing. 
Most people on this site , seem to be intelligent beings. 
Prove that intelligence by keeping the discussions to ONC.
first read, this is called Stockhouse...aka stock markets etc 
second read, this is Onc site,
Hoping for some Onc news soon.
all the best.

 


 

<< Previous
Bullboard Posts
Next >>